vimarsana.com

Page 4 - தேசிய மருத்துவ மேலாண்மை ப்ரோடொகால் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

All about AYUSH-64, polyherbal drug found useful in treating mild to moderate COVID cases

All about AYUSH-64, polyherbal drug found useful in treating mild to moderate COVID cases AYUSH-64 can be useful for the treatment of asymptomatic, mild and moderate COVID-19 infection cases, the Ministry of AYUSH said. Share Updated: May 3, 2021, 08:08 PM IST AYUSH-64, a drug developed for curing malaria in 1980, can be useful for the treatment of asymptomatic, mild and moderate COVID-19 infection cases, the Ministry of AYUSH said on Thursday. Central Council for Research in Ayurvedic Sciences (CCRAS) recently concluded clinical trials of the drug focusing on the management of asymptomatic, mild to moderate COVID-19 in collaboration with the Council of Scientific and Industrial Research (CSIR) and other research organizations and medical colleges across the country.

Remdesivir to be administered on medical prescription to severe COVID-19 patients : Centre to SC

Remdesivir to be administered on medical prescription to severe COVID-19 patients : Centre to SC A bench headed by Justice D Y Chandrachud was informed that there is a growing demand from some quarters to permit the use of Remdesivir even when a person is taking treatment at his own home. Share Via Email   |  A+A A- By PTI NEW DELHI: Antiviral drug Remdesivir is to be administered only after a medical prescription and limited to severe condition of COVID-19 patients strictly as per medical protocol, the Centre told the Supreme Court on Friday. A bench headed by Justice D Y Chandrachud was informed that there is a growing demand from some quarters to permit the use of Remdesivir even when a person is taking treatment at his own home under his own private medical supervision.

Remdesivir to be administered to severe COVID-19 patients with prescriptions: Centre tells SC

Remdesivir to be administered to severe COVID-19 patients with prescriptions: Centre tells SC A bench headed by Justice D Y Chandrachud was informed that there is a growing demand from some quarters to permit the use of Remdesivir even when a person is taking treatment at his own home under his own private medical supervision PTI | April 30, 2021 | Updated 21:49 IST Remdesivir is listed as investigational therapy in the National Clinical Management Protocol: COVID-19 Antiviral drug Remdesivir is to be administered only after a medical prescription and limited to severe condition of COVID-19 patients strictly as per medical protocol, the Centre told the Supreme Court on Friday.

Remdesivir to be administered on medical prescription to severe Covid-19 patients: Centre to SC | India News

Antiviral drug Remdesivir is to be administered only after a medical prescription and limited to severe condition of Covid-19 patients strictly as per medical protocol, the Centre told the Supreme Court on Friday. NEW DELHI: Antiviral drug Remdesivir is to be administered only after a medical prescription and limited to severe condition of Covid-19 patients strictly as per medical protocol, the Centre told the Supreme Court on Friday. A bench headed by Justice D Y Chandrachud was informed that there is a growing demand from some quarters to permit the use of Remdesivir even when a person is taking treatment at his own home under his own private medical supervision.

Poly herbal drug Ayush 64 is useful in mild to moderate Covid cases

Poly herbal drug Ayush 64 is useful in mild to moderate Covid cases April 30, 2021 Originally developed for treating malaria in 1980, it is now repurposed to treat Covid-19 Ayush 64, a poly herbal formulation developed by the Central Council for Research in Ayurvedic Sciences (CCRAS), could be effective in treating asymptomatic, mild and moderate Covid-19 infection if it is used as an adjunct to standard care, a statement from Ayush Ministry said on Thursday. The herbal drug, developed for treating malaria in 1980, but now repurposed to treat Covid-19 is found to be effective in studies carried out at three different centres – in Lucknow, Mumbai and Wardha, the statement said. This multi-centre study to evaluate safety and efficacy of Ayush 64 in Covid-19 management was carried out by Ayush in collaboration with the Council of Scientific and Industrial Research.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.